Aktie A2QLLC KRINGLE PHARMA, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Kringle Pharma, Inc.

Aktien

A2QLLC

JP3270790003

4884

Markt geschlossen - Japan Exchange
Andere Börsenplätze
 08:00:00 23.05.2024 		% 5 Tage % 1. Jan.
611 JPY -4,68 % Intraday Chart für Kringle Pharma, Inc. +3,56 % -18,75 %
09.02. Kringle Pharma, Inc. gibt Gewinnprognose für das Geschäftsjahr bis 30. September 2024 ab CI
2023 Kringle Pharma, Inc. gibt Gewinnprognose für das Geschäftsjahr bis 30. September 2024 ab CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024
Kringle Pharma, Inc. Completes Its Pre-Ind (Investigation New Drug) Meeting with the U.S. Food and Drug Administration Regarding the Development Plan of Kp-100It, A Lyophilized Formulation of Recombinant Human Hgf, for the Potential Treatment of Acute Spinal Cord Injury
Kringle's Preclinical Research Shows Encouraging Results for Dual Therapy Approach in Treating Acute Spinal Cord Injuries
Kringle Pharma, Inc. Announces Publication of Preclinical Results from Joint Research with Keio University on Severe Spinal Cord Injury
Kringle Pharma, Inc. Announces Last Patient Out in Phase 3 Study of KP-100IT for the Treatment of Acute Spinal Cord Injury
Kringle Pharma, Inc. announced that it has received ¥1.242 million in funding from Barclays Bank PLC (Tokyo Branch)
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023
Kringle Pharma, Inc. announced that it expects to receive ¥1.242 million in funding from Barclays Bank PLC (Tokyo Branch)
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023
Kringle Pharma Completes Patient Enrollment for Acute Spinal Cord Injury Treatment
Kringle Pharma, Inc. Announces Last Patient Enrolled in Phase Iii Study for the Treatment of Acute Spinal Cord Injury
Kringle Pharma Files Patent Application for Spinal Cord Injury Treatment
Kringle Pharma, Inc. Announces Patent Application Claims Priority for the Treatment of Chronic Spinal Cord Injury
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023
Bank of Japan's Dovish Policy Bolsters Japanese Shares; Shionogi Proceeds with Pediatric Trial of COVID-19 Vaccine
Kringle Pharma Enrolls Initial Candidate in Clinical Study for Vocal Impairment Treatment
Kringle Pharma, Inc. Announces First Patient Enrollment in Phase III Clinical Study for the Treatment of Vocal Fold Scar
Kringle Pharma, Inc. Provides Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury
Kringle Pharma, Inc. Provides Consolidated Earnings Guidance for Year Ending September 30, 2023
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QLLC Aktie
  4. Nachrichten Kringle Pharma, Inc.
  5. Andere Sprachen